Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Lantus Generic Name & Formulations
Legal Class
Rx
General Description
Insulin glargine (rDNA origin) 100 Units/mL; for SC inj; contains m-cresol.
How Supplied
Vials (10mL)—1; SoloStar prefilled pens (3mL)—5
Manufacturer
Generic Availability
NO
Lantus Indications
Indications
Diabetes mellitus (types 1 & 2).
Limitations of Use
Not for treating diabetic ketoacidosis.
Lantus Dosage and Administration
Adults and Children
Give by SC inj once daily at same time each day into abdominal area, thigh, or deltoid; rotate inj sites. Onset ~1hr, no pronounced peak, duration ≥24hrs. <6yrs: not established. ≥6yrs: individualize; monitor and adjust as needed.
Type 1 diabetes: Initially ⅓ of total daily insulin dose. Give remainder of the total dose as short-acting, premeal insulin. Insulin-naïve with type 2 diabetes: Initially 0.2 Units/kg or up to 10 Units once daily. May need to adjust amount, timing of short- or rapid-acting insulins and doses of any oral antidiabetics. Switching from once-daily Toujeo (insulin glargine 300 Units/mL): reduce initial Lantus dose by 20% of the previous Toujeo dose. Switching from once-daily NPH: initial Lantus dose should be the same as previous NPH dose. Switching from twice-daily NPH: reduce initial Lantus dose by 20% of the previous total NPH dose.
Lantus Contraindications
Contraindications
During episodes of hypoglycemia.
Lantus Boxed Warnings
Not Applicable
Lantus Warnings/Precautions
Warnings/Precautions
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyperglycemia or hypoglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Discontinue if hypersensitivity reactions occur. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
Lantus Pharmacokinetics
See Literature
Lantus Interactions
Interactions
Do not mix or dilute with other insulins. Increased risk of hypoglycemia with concomitant antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Reduced efficacy with concomitant atypical antipsychotics (eg, olanzapine, clozapine), steroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, protease inhibitors, somatropin, sympathomimetics (eg, albuterol, epinephrine, terbutaline), thyroid hormones; monitor more frequently. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, or reserpine may blunt hypoglycemia; monitor.
Lantus Adverse Reactions
Adverse Reactions
Hypoglycemia, local or systemic allergy, inj site reactions, lipodystrophy, pruritus, rash, edema, weight gain; hypokalemia.
Lantus Clinical Trials
See Literature
Lantus Note
Not Applicable
Lantus Patient Counseling
See Literature
